127868-60-4

Usage

Uses

Used in Pharmaceutical Industry:
2-(4-Pyrrolidin-1-yl-phenyl)-benzothiazole is used as an anti-inflammatory agent for its ability to reduce inflammation and alleviate associated symptoms.
Used in Oncology:
2-(4-Pyrrolidin-1-yl-phenyl)-benzothiazole is used as an anticancer agent for its potential to inhibit the growth of cancer cells, making it a candidate for further research in the development of novel cancer therapies.
Used in Antimicrobial Applications:
2-(4-Pyrrolidin-1-yl-phenyl)-benzothiazole is used as an antimicrobial agent for its ability to combat various types of bacteria, contributing to the development of new antimicrobial drugs.
Used in Antiviral Applications:
2-(4-Pyrrolidin-1-yl-phenyl)-benzothiazole is used as an antiviral agent, particularly against HIV-1 and other viruses, for its potential to inhibit viral replication and reduce viral load, offering a promising avenue for the development of new antiviral medications.

Upstream product

• 51980-54-2 4-(pyrrolidin-1-yl)benzaldehyde 
• 137-07-5 2-amino-benzenethiol 

Relevant academic research and scientific papers

Benzazole compounds

There are disclosed herein benzazole compounds, exemplified by 2-(4-aminophenyl)benzothiazole and analogues or salts thereof, which exhibit very significant selective cytotoxic activity in respect of tumor cells, especially breast cancer cells, and which provide potentially useful chemotherapeutic agents for treatment of breast cancer.

Antitumor benzothiazoles. 3. Synthesis of 2-(4- aminophenyl)benzothiazoles and evaluation of their activities against breast cancer cell lines in vitro and in vivo

A new series of 2-(4-aminophenyl)benzothiazoles substituted in the phenyl ring and benzothiazole moiety has been synthesized by simple, high- yielding routes. The parent molecule 5a shows potent inhibitory activity in vitro in the nanomolar range against a panel of human breast cancer cell lines, but is inactive (IC50 > 30 μM) against other cell types: activity against the sensitive breast lines MCF-7 and MDA 468 is characterized by a biphasic dose-response relationship. Structure-activity relationships derived using these cell types has revealed that activity follows the heterocyclic sequence benzothiazole > benzoxazole >> benzimidazole and that 2-(4-aminophenyl)benzothiazoles bearing a 3'-methyl- 9a, 3'-bromo- 9c, 3'- iodo- 9f, and 3'-chloro-substituent 9i are especially potent and their activity extends to ovarian, lung, and renal cell lines. Four compounds have been evaluated in vivo against human mammary carcinoma models in nude mice. Compound 9a showed the most potent growth inhibition against the ER+ (MCF- 7 and BO) and ER- (MT-1 and MT-3) tumors. Our efforts to identify a pharmacological mechanism of action for these intriguing compounds have not, as yet, been successful.